Deutsche Bank AG Takes Position in Syndax Pharmaceuticals, Inc. $SNDX

Deutsche Bank AG acquired a new position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 95,315 shares of the company’s stock, valued at approximately $2,084,000.

Other large investors also recently added to or reduced their stakes in the company. Larson Financial Group LLC grew its position in shares of Syndax Pharmaceuticals by 192.2% during the 3rd quarter. Larson Financial Group LLC now owns 2,922 shares of the company’s stock valued at $45,000 after acquiring an additional 1,922 shares during the period. Quantbot Technologies LP purchased a new position in Syndax Pharmaceuticals during the third quarter valued at $53,000. Smartleaf Asset Management LLC grew its holdings in Syndax Pharmaceuticals by 2,698.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 2,659 shares of the company’s stock valued at $55,000 after purchasing an additional 2,564 shares during the period. Lazard Asset Management LLC bought a new stake in Syndax Pharmaceuticals during the second quarter valued at about $66,000. Finally, Tower Research Capital LLC TRC increased its position in Syndax Pharmaceuticals by 103.3% in the second quarter. Tower Research Capital LLC TRC now owns 8,480 shares of the company’s stock worth $79,000 after buying an additional 4,308 shares in the last quarter.

Insider Transactions at Syndax Pharmaceuticals

In related news, CMO Nicholas A.J. Botwood sold 34,280 shares of the stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $18.00, for a total transaction of $617,040.00. Following the completion of the transaction, the chief marketing officer directly owned 60,885 shares of the company’s stock, valued at approximately $1,095,930. This represents a 36.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Michael A. Metzger sold 32,375 shares of the firm’s stock in a transaction that occurred on Wednesday, July 8th. The shares were sold at an average price of $24.24, for a total value of $784,770.00. Following the transaction, the chief executive officer owned 484,843 shares of the company’s stock, valued at $11,752,594.32. This represents a 6.26% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 105,914 shares of company stock valued at $2,120,789. Company insiders own 4.80% of the company’s stock.

Syndax Pharmaceuticals Trading Up 0.3%

Syndax Pharmaceuticals stock opened at $20.16 on Friday. Syndax Pharmaceuticals, Inc. has a 1 year low of $12.99 and a 1 year high of $25.59. The firm’s 50 day moving average price is $20.92 and its 200-day moving average price is $21.29. The company has a debt-to-equity ratio of 38.95, a current ratio of 6.77 and a quick ratio of 6.44. The stock has a market cap of $1.79 billion, a P/E ratio of -8.03 and a beta of 0.40.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its earnings results on Tuesday, August 4th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.10). The company had revenue of $72.79 million for the quarter, compared to analysts’ expectations of $79.36 million. Syndax Pharmaceuticals had a negative net margin of 87.52% and a negative return on equity of 372.94%. The business’s revenue was up 91.8% on a year-over-year basis. During the same period in the previous year, the business posted ($0.83) earnings per share. On average, equities analysts predict that Syndax Pharmaceuticals, Inc. will post -2.01 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently commented on the company. HC Wainwright decreased their price objective on Syndax Pharmaceuticals from $40.00 to $38.00 and set a “buy” rating on the stock in a research note on Wednesday, August 5th. UBS Group cut their price objective on Syndax Pharmaceuticals from $37.00 to $33.00 and set a “buy” rating for the company in a research note on Friday, August 21st. JPMorgan Chase & Co. reduced their target price on shares of Syndax Pharmaceuticals from $44.00 to $40.00 and set an “overweight” rating for the company in a report on Tuesday, August 11th. Barclays raised their target price on shares of Syndax Pharmaceuticals from $35.00 to $37.00 and gave the stock an “overweight” rating in a research note on Friday, May 1st. Finally, Bank of America reiterated a “buy” rating on shares of Syndax Pharmaceuticals in a research report on Wednesday, August 5th. Twelve equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $41.55.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.